Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer

Pham, Thong Quang; Hoang, Van-Thinh; Phan, Thanh-Thang; Nguyen, Thuy-Hang; Nguyen-Bui, Ngoc-Diep

doi:10.14744/ejmo.2018.0114

Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer

Hang NGUYEN, (Cho Ray Hospital, Department of Clinical Pathology, Ho Chi Minh City, Vietnam)

Thinh HOANG, (Cho Ray Hospital, Department of Clinical Pathology, Ho Chi Minh City, Vietnam)

Diep NGUYEN, (Cho Ray Hospital, Department of Clinical Pathology, Ho Chi Minh City, Vietnam)

Thong PHAM, (Cho Ray Hospital, Department of Clinical Pathology, Ho Chi Minh City, Vietnam)

Thang PHAN (Cho Ray Hospital, Department of Clinical Pathology, Ho Chi Minh City, Vietnam)

Eurasian Journal of Medicine and Oncology

0 0

Yıl: 2019 Cilt: 3 Sayı: 2 Sayfa Aralığı: 101 - 107 Metin Dili: İngilizce DOI: 10.14744/ejmo.2018.0114 İndeks Tarihi: 22-04-2020

Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer

Öz:

Objectives: This study aims to describe the characteristics of epidermal growth factor receptor (EGFR) mutations incorrelation with clinical features of Vietnamese non-small cell lung cancer (NSCLC), and identify the predictive factorfor the incidence of EGFR mutations.Methods: A total of 1.548 newly diagnosed NSCLC patients were selected for this retrospective study. EGFR mutationswere detected in the tumor, lymph node tissue and pleural fluid by the pyrosequencing method.Results: EGFR mutations were detected in 623 patients (40.2%). Mutations were more frequent in the female patient(p<0.001), in adenocarcinoma (p=0.004), in pleural effusion sample (p=0.002), in the low-intermediate grade of thetumor (p<0.001), and in those with CK7-positive (p=0.001) and TTF1-positive result (p<0.001). Notably, the low gradeof the tumor (p<0.001), TTF1-positive marker (p=0.001) and pleural fluid (p=0.002) were detected as independent factors for the higher incidence of EGFR mutations in multivariable analysis. In addition, CK7 marker played the role as anindependent factor when TTF1 marker was not applied (p=0.011).Conclusion: EGFR mutations occur with high frequency in Vietnamese NSCLC patients. Histologic grade, TTF1 marker,and sample type are independent factors for the incidence of EGFR mutations.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1.Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al; Global Burden of Disease Cancer Collaboration. Global, Regional, and National cancer incidence, Mortality, Years of life lost, Years lived with disability, and Disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524–48.
2. Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology 2012;25:347–69.
3. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small cell lung cancer with Erlotinib or Gefitinib. N Engl J Med 2011;364:947–55.
4. Kohler J, Schuler M. Afatinib, Erlotinib and Gefitinib in the firstline therapy of EGFR mutation-positive lung adenocarcinoma: A review. Onkologie 2013;36:510–8.
5. Rossel R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al; Spanish Lung Cancer Group. Screening for Epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958–67.
6. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892–1.
7. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014;9:154–62.
8. Arrieta O, Cardona A, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated frequency of EGFR and KRAS mutations in Non-small-cell lung cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol 2015;10:838–43.
9. Vu HA, Xinh PT, Ha HT, Hanh NT, Bach ND, Thao DT, et al. Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer. Asia Pac J Clin Oncol 2016;12:86– 90.
10. Sugio K, Uramoto H, Ono K, Oyama T, Hanagiri T, Sugaya M, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94:896–903.
11. Wei W, Mao NQ, Ning SF, Li JL, Liu HZ, Xie T, et al. An analysis of EGFR mutations among 1506 cases of Non-small cell lung cancer patients in Guangxi, China. Plos One 2016;11:e0168795.
12. Zhang Q, Zhu L, Zhang J. Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients. BMC Cancer 2015;15:88.
13. Joshi A, Zanwar S, Noronha V, Patil VM, Chougule A, Kumar R, et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther 2017;10:1859–63.
14. Sun Y, Yin X, Wen MM, Zhang J, Wang XJ, Xia JH, et al. EGFR mutations subset in Chinese lung squamous cell carcinoma patients. Mol Med Rep 2018;17:7575–84.
15. Taniguchi Y, Matsumoto Y, Furukawa R, Ohara S, Usui K. The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. Int J Clin Oncol 2018;23:452–7.
16. Wang Sh, Wang Zh. EGFR mutations in patients with non-sNguyen et al. Factors for the Incidence of EGFR Mutations in NSCLC / doi: 10.14744/ejmo.2018.0114 mall cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. Int J Clin Exp Med 2014;7:1967–78.
17. Shiau CJ, Babwah JP, da Cunha Santos G, Sykes JR, Boerner SL, Geddie WR, et al. Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol 2014;9:947–56.
18. Jin Y, Chen M, Yu X. Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Sci Rep 2016;6:31636.
19. Lin CY, Wu YM, Hsieh MH, Wang CW, Wu CY, Chen YJ, et al. Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma. PloS One 2017;12:e0186567.
20. Levy M, Lyon L, Barbero E, Wong J, Suga JM, Sam D, et al. Histologic grade is predictive of incidence of epidermal growth factor receptor mutations in metastatic lung adenocarcinoma. Med Sci 2017;5. pii: E34.
21. Feng Y, Zhou J, Chen S, Jiang Y, Zhou Y. Relationship between EGFR gene mutation and serum tumor biomarkers in advanced lung adenocarcinoma. Int J Clin Exp Pathol 2016;9:250–5.
22. Jin B, Dong Y, Wang HM, Huang JS, Han BH. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. Acta Pharmacologica Sinica 2014;35:373–80.
23. Wang L, Lou T, Zhong H, Mo Q, Dong Y, Jia A, et al. Predictive value of serum markers for targeted treatment in advanced lung adenocarcinoma. Int J Clin Exp Med 2016;9:7297–302.
24. Yang ZM, Ding XP, Pen L, Mei L, Liu T. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pac J Cancer Prev 2014;15:3451–5.
25. Pan JB, Hou YH, Zhang GJ. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. Asian Pacific J Cancer Prev 2013;14:695–700.
26. Vincenten J, Smit EF, Vos W, Grünberg K, Postmus PE, Heideman DA, et al. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-Mutation analysis in patients with non-small-cell lung cancer. J Thorac Oncol 2012;7:1522–7.
27. Shanzhi W, Yiping H, Ling H, Jianming Z, Qiang L. The Relationship between TTF-1 expression and EGFR mutations in lung Adenocarcinomas. Plos One 2014;9:e95479.
28. Sheffield BS, Bosdet IE, Ali RH, Young SS, McNeil BK, Wong C, et al. Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer. Curr Oncol 2014;21:305–8.
29. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no c of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7:323–30.
30. Huang TW, Lin KF, CH, Chang H, Lee SC, Shieh YS. The role of thyroid transcription factor-1 and tumor diferentiation in resected lung adenocarcinoma. Sci Rep 2017;7:14222.
31. Chung KP, Huang YT, Chang YL, Yu CJ, Yang CH, Chang YC, et al. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest 2012;141:420–8.
32. Zhao Q, Xu S, Liu J, Li Y, Fan Y, Shi T, et al. Thyroid transcription factor-1 expression is signifcantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in chinese patients with lung adenocarcinoma. Onco Targets Ther 2015;8:2469–78.
33. Krawczyk P, Ramlau R, Chorostowska Wynimko J, Powrózek T, Lewandowska MA, Limon J, et al. The effcacy of EGFR gene mutation testing in various samples from non small cell lung cancer patients: a multicenter retrospective study. J Cancer Res Clin Oncol 2015;141:61–8.
34. Zhang Y, Wang R, Li Y, Pan Y, Hu H, Zhang Y, et al. Negative thyroid transcription factor 1 expression defines an unfavorable subgroup of lung adenocarcinomas. J Thorac Oncol 2015;10:1444–50.
35. Hagiwara H, Kobayashi K. Importance of the cytological samples for the epidermal growth factor receptor gene mutation test for non-small cell lung cancer. Cancer Sci 2013;104:291–7.
36. Mohar B, Jezek SS, Molek KR, Stemberger C, Kurpis M, Kupanovac Z, et al. Detection of an EGFR mutation in cytological specimens of lung adenocarcinoma. Cytopathology 2016;27:444–51.
37. Han X, Zhang Z, Wu D, Shen Y, Wang S, Wang L, et al. Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on Chinese population. Transl Oncol 2014;7:795–9.
38. Szumera-Ciećkiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol 2013;6:2800–12.
39. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J 2013;41:1409–18.
40. Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Ja cobse KC, Jiwa NM, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol 2012;35:189–96.
41. Zou JY, Bella AE, Chen ZG, Han ZQ, Su CH, Lei YY, et al. EJMO Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation. J Int Med Res 2014;42:1110–7.
42. Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC, Yang PC, et al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci Rep 2015;5:13574.
43. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med 2012;186:487–92.
44. Spella M, Giannou AD, Stathopoulos GT. Switching off malignant pleural effusion formation-fantasy or future? J Thorac Dis 2015;7:1009–20.
45. Wang MC, Wang CL, Chen TL, Chang JW, Lu JJ, Chang PY, et al. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clin Chem Lab Med 2017;55:1979–86.
46. Yang J, Lee OJ, Son SM, Woo CG, Jeong Y, Yang Y, et al. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors. Cancer Res Treat 2018;50:908–16.

APA	Nguyen T, Hoang V, Nguyen-Bui N, Pham T, Phan T (2019). Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. , 101 - 107. 10.14744/ejmo.2018.0114
Chicago	Nguyen Thuy-Hang,Hoang Van-Thinh,Nguyen-Bui Ngoc-Diep,Pham Thong Quang,Phan Thanh-Thang Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. (2019): 101 - 107. 10.14744/ejmo.2018.0114
MLA	Nguyen Thuy-Hang,Hoang Van-Thinh,Nguyen-Bui Ngoc-Diep,Pham Thong Quang,Phan Thanh-Thang Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. , 2019, ss.101 - 107. 10.14744/ejmo.2018.0114
AMA	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. . 2019; 101 - 107. 10.14744/ejmo.2018.0114
Vancouver	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. . 2019; 101 - 107. 10.14744/ejmo.2018.0114
IEEE	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T "Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer." , ss.101 - 107, 2019. 10.14744/ejmo.2018.0114
ISNAD	Nguyen, Thuy-Hang vd. "Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer". (2019), 101-107. https://doi.org/10.14744/ejmo.2018.0114

APA	Nguyen T, Hoang V, Nguyen-Bui N, Pham T, Phan T (2019). Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology, 3(2), 101 - 107. 10.14744/ejmo.2018.0114
Chicago	Nguyen Thuy-Hang,Hoang Van-Thinh,Nguyen-Bui Ngoc-Diep,Pham Thong Quang,Phan Thanh-Thang Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology 3, no.2 (2019): 101 - 107. 10.14744/ejmo.2018.0114
MLA	Nguyen Thuy-Hang,Hoang Van-Thinh,Nguyen-Bui Ngoc-Diep,Pham Thong Quang,Phan Thanh-Thang Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology, vol.3, no.2, 2019, ss.101 - 107. 10.14744/ejmo.2018.0114
AMA	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 101 - 107. 10.14744/ejmo.2018.0114
Vancouver	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 101 - 107. 10.14744/ejmo.2018.0114
IEEE	Nguyen T,Hoang V,Nguyen-Bui N,Pham T,Phan T "Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer." Eurasian Journal of Medicine and Oncology, 3, ss.101 - 107, 2019. 10.14744/ejmo.2018.0114
ISNAD	Nguyen, Thuy-Hang vd. "Histologic Grade with Thyroid Transcription Factor 1 and Sample Type Serve as Independent Factors for the Incidence of EGFR Mutations in Non-small Cell Lung Cancer". Eurasian Journal of Medicine and Oncology 3/2 (2019), 101-107. https://doi.org/10.14744/ejmo.2018.0114